New drug trial aims to slow ALS progression
NCT ID NCT06441682
Summary
This study is testing an investigational drug called ARGX-119 in adults with ALS (amyotrophic lateral sclerosis). The main goals are to check the drug's safety and see if it can help slow the loss of muscle function. About 60 participants will receive different doses of the drug or a placebo for a period, then all will receive the drug, with the study lasting up to 100 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus Universitets Hospital
Aarhus, 8200, Denmark
-
Akademiskt specialistcentrum Karolinska Institutet
Stockholm, 113 61, Sweden
-
Bispebjerg University Hospital
Copenhagen, 2400, Denmark
-
CHU Bretonneau
Tours, 37000, France
-
Hôpital La Pitié Salpêtrière
Paris, 75013, France
-
Kaye Edmonton Clinic
Edmonton, 11400, Canada
-
Montreal Neurological Institute and Hospital
Montreal, H3A 2B4, Canada
-
UMC Utrecht
Utrecht, 3584 CX, Netherlands
-
UZ Leuven
Leuven, 3000, Belgium
Conditions
Explore the condition pages connected to this study.